Division of Neonatology, Children's and Women's Health Centre
Vancouver, British Columbia, Canada
NCT Number: NCT00358748
The purpose of this study is to investigate the early use of hydrocortisone in hypotensive very low birth weight infants.
Based on the observations that:
* hypotension is a common problem in very low birthweight infants and is associated with brain injury and poor neurological outcomes; * some infants are refractory to standard treatment (volume expansion and vasopressors), which is not exempt of adverse effects; * relative adrenal insufficiency has been described in this population; we hypothesize that hydrocortisone is effective in the treatment of hypotension in this population and reduce the need for vasopressors.
Looking for future studies?
Notify Me48 hour–30 week
All sexes
Interventional
Phase 3
Vancouver, British Columbia, Canada
Eligible infants will be randomly assigned to receive hydrocortisone or placebo, using sequentially numbered, preassigned treatment designations in sealed, opaque envelopes. The study drug will be randomly assigned to each patient number, in advance, using a computer-based random number generator.
Hydrocortisone and placebo doses will be prepared and provided by the hospital pharmacy following the assigned study number. Active and placebo drug solutions will be completely indistinguishable.
Infants of multiple gestations will be randomized as separate subjects. Crossover between study groups is not allowed. Physicians involved in the care of the infants will be blinded to treatment group allocation.
If the infant remains hypotensive after a Normal Saline (NS) bolus 10 ml/kg, blood for serum cortisol level determination will be drawn and hydrocortisone or an equivalent volume of NS placebo will be administered intravenously as follows: first dose immediately after randomization 2 mg/kg; 6 hours after 1 mg/kg q6h for 3 doses; followed by 0.5 mg/kg q6hs for 4 doses. If an infant responds to the initial dose of NS but becomes hypotensive within 1 hour after will also be randomized, otherwise another NS bolus could be administered.
Initiation and escalation of inotropes:
Concurrently with the first dose of study drug, dopamine infusion will be started at 5 mcg/kg/minute, increasing stepwise to a maximum of 15 mcg/kg/minute. If hypotension persists an epinephrine infusion at 0.05 mcg/kg/min will be added and increased stepwise if necessary. The aim is to maintain mean blood pressure (MBP) above the hypotensive limit defined in the inclusion criteria.
Weaning of inotropes:
Once normotension has been maintained for 1 hour or MBP > 40 mmHg for 15 minutes, weaning should be started. Dopamine infusion will be reduced first, as tolerated, to 5 mcg/kg/minute. If the subject is on epinephrine infusion the dose will be reduced stepwise to 0.05 mcg/kg/minute and discontinued. When the subject is off epinephrine and/or dopamine at 5 mcg/kg/minute, dopamine will be discontinued. If at any time hypotension recurs, weaning should be held and increased inotropes dose as per escalation algorithm.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
See detailed description above.
Time frame: 7 days
Time frame: 7 days
University of British Columbia
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06257316
Cardiovascular Diseases, Hypotension
View Trial DetailsNCT05347238
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Extreme Prematurity
Phoenix, Arizona, United States
View Trial DetailsNCT03136172
Cardiovascular Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Incheon, South Korea
View Trial DetailsNCT00874393
Blood Pressure, Cardiovascular Diseases
Birmingham, Alabama, United States
View Trial Details